PureTech Health Yönetim

Yönetim kriter kontrolleri 1/4

PureTech Health CEO'su Bharatt Chowrira, Apr2024 tarihinde atandı, in görev süresi bir yıldan az. in toplam yıllık tazminatı $ 2.49M olup, şirket hissesi ve opsiyonları dahil olmak üzere 23.1% maaş ve 76.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.42% ine doğrudan sahiptir ve bu hisseler £ 1.73M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 0.7 yıl ve 8.1 yıldır.

Anahtar bilgiler

Bharatt Chowrira

İcra Kurulu Başkanı

US$2.5m

Toplam tazminat

CEO maaş yüzdesi	23.1%
CEO görev süresi	less than a year
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	less than a year
Yönetim Kurulu ortalama görev süresi	8.1yrs

Son yönetim güncellemeleri

Recent updates

Is PureTech Health (LON:PRTC) Using Debt Sensibly?

Nov 15

What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today

Aug 27

PureTech Health plc Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 18

We're Not So Sure You Should Rely on PureTech Health's (LON:PRTC) Statutory Earnings

Jan 18

CEO Tazminat Analizi

Bharatt Chowrira'un ücretlendirmesi PureTech Health'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$82m
Mar 31 2024	n/a	n/a	-US$74m
Dec 31 2023	US$2m	US$575k	-US$66m
Sep 30 2023	n/a	n/a	-US$56m
Jun 30 2023	n/a	n/a	-US$47m
Mar 31 2023	n/a	n/a	-US$49m
Dec 31 2022	US$988k	US$530k	-US$50m
Sep 30 2022	n/a	n/a	-US$32m
Jun 30 2022	n/a	n/a	-US$14m
Mar 31 2022	n/a	n/a	-US$37m
Dec 31 2021	US$1m	US$500k	-US$61m

Tazminat ve Piyasa: Bharatt 'nin toplam tazminatı ($USD 2.49M ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 983.02K ).

Tazminat ve Kazançlar: Bharatt şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Bharatt Chowrira (59 yo)

less than a year

Görev süresi

US$2,490,425

Tazminat

Dr. Bharatt M. Chowrira, J. D. Ph. D. served as Chief Business and Operating Officer at PureTech Health plc. since January 2022 until 2024 and serves as its Chief Executive Officer from April 09, 2024 and...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bharatt Chowrira	CEO & Executive Director	less than a year	US$2.49m	0.42% £ 1.7m
Daphne Zohar	Founder	no data	US$4.74m	3.35% £ 13.7m
Robert Langer	Co-Founder & Non-Executive Director	no data	US$135.00k	1.15% £ 4.7m
Eric Elenko	Co-Founder & President	less than a year	Veri yok	Veri yok
David Elmaleh	Co-Founder & Senior Advisor	no data	Veri yok	Veri yok
Lauren White	Chief Financial Officer	no data	Veri yok	Veri yok
Eric Green	Chief Operating Officer	less than a year	Veri yok	Veri yok
Allison Talbot	Head of Communications & Investor Relations	no data	Veri yok	Veri yok
Charles Sherwood	General Counsel & Company Secretary	less than a year	Veri yok	Veri yok
Spencer Ball	Senior Vice President of Human Resources	4.3yrs	Veri yok	Veri yok
Aleksandra Filipovic	Head of Oncology	4.3yrs	Veri yok	Veri yok
Cheryl Murphy	Head of Grants Management & Strategy	4.3yrs	Veri yok	Veri yok

0.7yrs

Ortalama Görev Süresi

56yo

Ortalama Yaş

Deneyimli Yönetim: PRTC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Bharatt Chowrira	CEO & Executive Director	3.8yrs	US$2.49m	0.42% £ 1.7m
Daphne Zohar	Founder	less than a year	US$4.74m	3.35% £ 13.7m
Robert Langer	Co-Founder & Non-Executive Director	no data	US$135.00k	1.15% £ 4.7m
David Elmaleh	Co-Founder & Senior Advisor	no data	Veri yok	Veri yok
Raju Kucherlapati	Chair & Senior Independent Director	10.8yrs	US$172.50k	1.05% £ 4.3m
John LaMattina	Independent Non-Executive Director	15.8yrs	US$137.75k	0.61% £ 2.5m
Bennett Shapiro	Board Advisor	4.4yrs	US$68.94k	Veri yok
R. Anderson	Advisor	8.1yrs	Veri yok	Veri yok
James Collins	Advisor	9yrs	Veri yok	Veri yok
Donald Ingber	Senior Advisor	8.8yrs	Veri yok	Veri yok
Frederick Frank	Senior Advisor	no data	Veri yok	Veri yok
Sharon Barber-Lui	Independent Non-Executive Director	2.7yrs	US$135.00k	0.016% £ 66.1k

8.1yrs

Ortalama Görev Süresi

74yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PRTC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 8.1 yıldır).

PureTech Health Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

PureTech Health plc Appoints Sandi Peterson to Its Board of Directors

PureTech Health plc Appoints Lauren White as Chief Financial Officer

Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024

PureTech Health plc Appoints David Wheadon to Its Board of Directors

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

Recent updates

Consensus revenue estimates decrease by 78%

PureTech Health plc Appoints Sandi Peterson to Its Board of Directors

Is PureTech Health (LON:PRTC) Using Debt Sensibly?

PureTech Health plc Appoints Lauren White as Chief Financial Officer

Puretech Health plc Presents Research Highlighting Burden of Idiopathic Pulmonary Fibrosis and Use of A Bayesian Stat Analysis for Lyt-100 (Deupirfenidone) At Chest 2024 Annual Meeting

PureTech Health plc Announces KarXT Receives U.S. Food and Drug Administration Approval for the Treatment of Schizophrenia in Adults

Consensus EPS estimates upgraded to US$0.55 loss

Consensus revenue estimates decrease by 57%

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 973%, EPS downgraded

First half 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Puretech Health plc Appoints Michele Holcomb as Independent Non-Executive Director, Effective September 23, 2024

PureTech Health plc to Report First Half, 2024 Results on Aug 28, 2024

PureTech Health plc Appoints David Wheadon to Its Board of Directors

PureTech Health plc Appoints Raju Kucherlapati as Chair of Board of Directors

PureTech Health plc (LSE:PRTC) announces an Equity Buyback for 33,500,000 shares, representing 12.37% for $100 million.

Seaport Therapeutics Announces Board of Directors Changes and Makes Key Executive Appointments

PureTech Health plc, Annual General Meeting, Jun 13, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

PureTech Health plc to Report Fiscal Year 2023 Results on Apr 25, 2024

PureTech Health plc Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis

PureTech Health plc Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers

PureTech Health plc Announces Chief Executive Officer Changes

New minor risk - Financial data availability

New major risk - Revenue and earnings growth

Puretech Health plc Presents Data from Phase 1 Trial of Lyt-200 Targeting Galectin-9 in Solid Tumors At the Esmo Immuno-Oncology Congress 2023

Puretech Health plc Announces Topline Results from Its Phase 2A, Randomized, Placebo-Controlled, Proof-Of-Concept Trial of LYT-300

PureTech Presents Data from LYT-100 (Deupirfenidone) Trial in Healthy Older Adults At Chest Annual Meeting

Puretech Announces the Appointment of Robert Lyne as Chief Portfolio Officer

Consensus revenue estimates fall by 88%

First half 2023 earnings: EPS and revenues miss analyst expectations

PureTech Health plc to Report First Half, 2023 Results on Aug 29, 2023

PureTech Health plc Receives Up to $11.4 Million from U.S. Department of Defense to Advance LYT-300 (Oral Allopregnanolone) for Fragile X-Associated Tremor/Ataxia Syndrome

Puretech Health plc Initiates Phase 2A Clinical Trial of Lyt-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 29%

PureTech Health plc to Advance LYT-300 (Oral Allopregnanolone) for the Potential Treatment of Anxiety Disorders and Postpartum Depression

PureTech Health plc Announces Executive Changes

PureTech Health plc Announces Topline Results from the Completed, Multi-Part Phase 1 Trial of LYT-300

PureTech Health plc Presents Data for LYT-200 Targeting Galectin-9 in Preclinical Leukemia Cancer Models at the 64th American Society of Hematology Annual Meeting

PureTech Announces New Therapeutic Candidate, LYT-310, an Oral Form of Cannabidiol (CBD) Leveraging PureTech’s Glyph™ Platform

Nektar Therapeutics (NasdaqGS:NKTR) cancelled the acquisition of PureTech Health plc (LSE:PRTC).

Nektar Therapeutics (NasdaqGS:NKTR) submitted a non-binding proposal to acquire PureTech Health plc (LSE:PRTC).

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

PureTech Health plc Presents Data for LYT-100 (Deupirfenidone) Supporting Design of Dose-Ranging Trial in Idiopathic Pulmonary Fibrosis (IPF) at European Respiratory Society International Congress 2022

Consensus forecasts updated

What You Need To Know About The PureTech Health plc (LON:PRTC) Analyst Downgrade Today

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

PureTech Health plc to Report First Half, 2022 Results on Aug 25, 2022

PureTech Announces Phase 3 Study of Digital Treatment in Children with ADHD Begun by Shionogi in Japan

PureTech Health plc Announces New Akili Data in Lupus

Puretech Health plc Announces the Initiation of A Clinical Study of LYT-100

PureTech Health plc(LSE:PRTC) dropped from FTSE 350 (Ex Investment Companies) Index (GBP)

PureTech Health plc Reports Results from Phase 2 Study of LYT-100-COV in Post-Acute "Long" COVID with Respiratory Complications

PureTech Health plc and Akili Interactive Labs, Inc. Appoints Matt Franklin as President and Chief Operating Officer, Effective June 21, 2022

PureTech Health plc Presents Additional Phase 1 Data for LYT-100

Consensus forecasts updated

Is PureTech Health (LON:PRTC) A Risky Investment?

Full year 2021 earnings: EPS and revenues exceed analyst expectations

PureTech Health plc, Annual General Meeting, Jun 15, 2022

Puretech Founded Entity Vedanta Biosciences Publishes Phase 1A/1B Results for Lead Program Ve303 in Cell Host & Microbe and Highlights Plann Presentations of Phase 2 Ve303 Results

PureTech Health plc Announces Publication of Research from Collaborators Demonstrating PureTech’s Glyph™ Platform Enhances Oral Absorption of Buprenorphine

PureTech Health plc to Report Fiscal Year 2021 Results on Apr 26, 2022

President recently bought UK£51k worth of stock

PureTech Health plc Announces LYT-100 Achieves 50% Reduction in Healthy Older Adults Experiencing GI-Related Adverse Events Compared to Pirfenidone

President recently bought UK£73k worth of stock

Health Check: How Prudently Does PureTech Health (LON:PRTC) Use Debt?

PureTech Health plc Reports on the Key Progress Made Across its Wholly Owned Programs 1 and Founded Entities 2 in 2021

PureTech Health plc's Lymphatic Platform Candidate Human Study